Introduction
Prenatal rather than postnatal transfer of functional genes to correct genetic disease offers several advantages. Expanding stem cell populations may be transduced, possibly achieving a permanent therapeutic effect and lasting prevention of an inherited disease before the onset of early tissue damage. Additionally, immune tolerance to vector and transgenic protein may be induced, avoiding immune reactions to repeated postnatal treatment at the DNA or protein level. 1 The treatment of genetic diseases would ideally require safe and permanent gene transfer followed by transgene expression for the lifetime of the individual. The majority of strategies in fetal gene therapy research have concentrated so far on the use of adenoviral vectors as excellent pathfinders because they confer efficient gene transfer and expression to a broad range of tissues without being restricted to dividing cells, a pre-requisite for the use of MLV-derived retroviral vectors. They have been used in several fetal studies in different animal models to explore various application routes and have demonstrated successful transgene expression in the fetal airways, gut, liver, adrenal glands, and vascular system. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Their immunogenicity has been exploited to study the possibility of fetal immune tolerance after prenatal administration. [15] [16] [17] However, loss of these episomal DNA vectors during subsequent cell divisions following infection severely curtails their applicability to long-term fetal gene therapy.
Integrative vectors such as retroviruses and lentiviruses should theoretically be better suited for stable and permanent gene expression. In particular, lentiviruses that can infect nondividing cells 18 have been shown to provide more efficient gene transfer and sustained gene expression in vivo. 20, 21 MLV-based vectors have been applied by intratracheal, intrahepatic, and intraperitoneal injection to fetal sheep and rats; 18, [22] [23] [24] [25] however, only low levels of transgene expression were observed in all cases. Intraperitoneal vector injection to fetal sheep at 60 days of gestation resulting in marker gene expression in haematopoietic cells until at least 40 months was attributed both to the expression from an integrating vector system as well as to the induction of immune-tolerance against the transgenic protein. 24 In contrast, intraperitoneal or intrahepatic application of MLV-derived retroviral or HIV-derived lentiviral vectors to the early gestation rhesus monkey failed to provide postnatal marker gene expression. This was interpreted as a result of 'vector silencing' since integrated vector was detectable for up to 10 months. 25 We have recently achieved long-term postnatal tolerance against human factor IX in immunocompetent mice after systemic adenovirus-mediated delivery via the fetal yolk sac vessels (S Waddington, in press). We have now combined this highly efficient delivery route with the use of the novel equine infectious anaemia virus (EIAV) pseudotyped with the VSV-G envelope to achieve high-level, long-term postnatal gene expression of b-galactosidase in several organs, especially in the liver.
Results

Access to the fetal circulation via the yolk sac vessels
The fetal circulation of the mouse is, unlike larger animals and humans, technically difficult to access via the umbilical vein. However, the yolk sac vessels provide an alternative and physiologically equivalent extraembryonic route to the fetal circulation. Situated in the plane of the yolk sac membrane they are readily visible and accessible through the wall of the exposed uterus without interference with the amniotic cavity or the embryo proper. As blood flow mechanics have been suggested to influence the patterns of transgene expression, 26 we first investigated the extent of vector spread 5 min after injection of colloidal carbon (Figure 1 ). It is well distributed throughout the entire fetal circulation, localizing especially in the liver and heart and, in spite of physiological shunting through the foramen ovale and ductus Botalli, also in the lungs.
Broad organ transduction and time-dependent tissue differences in postnatal transgene expression after injection of EIAV-based vectors in utero
We then injected an EIAV-based vector into the circulation of eight fetuses to determine the extent and length of b-galactosidase expression. Three fetuses were killed on day 3 after injection. All others were allowed to come to birth. One each was killed on days 7 and 14 postinjection, respectively. Liver biopsies were taken from the three remaining mice on day 28, two were killed on day 79, while one was biopsied again on day 168 (6 months) and then killed after one year.
A uniform light blue staining of the fetal liver was detectable macroscopically in all three fetuses 3 days after gene delivery. This was manifested histologically as non-nuclear localized staining in almost 100% of liver cells (Figure 2, upper Despite the uniform access to the whole body by systemic delivery, as shown by the colloidal carbon injection, in addition to liver expression we found distinct differences in the tissue distribution of transgene expression with time. On day 7, expression was only obvious in the capillary endothelia of the brain. On day 7, expression was only apparent in the heart muscle. On day 14, strong expression was found in the heart and skeletal muscle, and on day 79 further expression became apparent in interstitial cells in the lung, in the brain, where there were long striations of staining indicating axonal expression, and in the kidney tubules of the renal medulla and, occasionally, the renal cortex ( Figure 2 , lower panel). In the animal sacrificed after 1 year, staining was clearly observed in skeletal and cardiac muscle. Poor staining was also observed in the bronchi and brain but not in the kidney (data not shown). Agematched control tissue for each time point of sacrifice, including the liver at 3 days and 1 year ( Figure 2 , lower panel), were negative for b-galactosidase activity; however, endogenous b-galactosidase activity was found routinely in the gut of animals at all time points.
Detection of vector spread and analysis of germ-cell transduction after in utero EIAV gene delivery
The presence of the EIAV lentivirus vector in all tissues was determined in the remaining fetally treated adult killed after 1 year postinjection by PCR. Primers were designed to amplify the region within the vector between the 5 0 cppt DNA sequence and the b-galactosidase reporter gene to produce a 999 bp fragment. PCR spread is shown for each tissue in Table 1 . Sensitive Taqman PCR was used to determine the number of EIAV genomes per cell in the treated liver sample positive after 1 year. Whereas negative control mouse DNA showed essentially no presence of vector, the treated liver sample gave an average of 3.6 EIAV virus copies per cellular genome. To determine whether injection of the EIAV lentivirus into the fetal circulation results in germ-line transmission, Taqman PCR 27 was also used to identify the number of vector genomes in the sperm of a male mouse 75 days postinjection. DNA extracted from the ejaculate of an untreated mouse and liver DNA from an EIAV fetally treated mouse were used as positive and negative Long-term transgene expression after fetal gene delivery SN Waddington et al controls, respectively. The number of EIAV vector copies per haploid genome was one-tenth of the background value measured in nontreated control sperm and therefore sperm samples were negative for vector presence.
Adult portal vein injection of EIAV-based vectors fail to give transgene expression
To determine whether a similar level of reporter gene expression could be achieved with the SMART2Z vector in adult animals, we injected two mice intravenously. One was partially hepatectomized the day before vector administration. We observed no hepatic galactosidase staining 3 days later in either mouse.
Discussion
Access to the fetal circulation via the umbilical vein using minimally invasive ultrasound guided injection is an Figure 2 Upper panel. Representative sections of fetal livers harvested at 72 h, 7, 14, 28, 79, 168 days and 1 year after yolk sac injection of high titre EAIV SMART2Z lentiviral vector (n¼1, 1, 3, 1 and 1, respectively). Uniform hepatocyte staining is observed after 72 h followed by the emergence of clusters of bgalactosidase-stained hepatocytes to day 79. Macroscopic appearance of liver sections (top row, Â 10). Microscopic analyses (bottom row, Â 400). Agematched noninfected control livers of 3 days and 1-year-old animals are shown in the lower panel. Lower panel. Representative sections of fetal tissues harvested at 72 h, 7, 14, 79 days and 1 year after yolk sac injection of high titre EAIV SMART2Z lentiviral vector (n¼1, 1, 3 and 1, respectively). Highlevel staining is observed after 72 h and 79 days in brain, 7, 14 and 79 days in heart and 14 and 79 days in skeletal muscle. Low-level expression is shown in lung and kidney at 79 days postinjection. Macroscopic appearance of tissues (left columns, Â 10). Microscopic analysis (right column, Â 400).
Long-term transgene expression after fetal gene delivery SN Waddington et al established technique in fetal medicine, which has been exploited for systemic gene delivery to fetal sheep. 28 Since the efficacy of vector delivery to the fetal circulation cannot be evaluated in murine models via this procedure, alternative injection routes directly into the liver 6 and placenta 29 have been investigated. Liver injection results in limited gene delivery to other tissues 30 and placental injection carries the disadvantage of vector loss within the placenta as well as the risk of vector spread into the maternal circulation. In contrast, yolk sac injection, similar to umbilical vein application, will deliver the vector on first passage to the liver as well as to the general circulation as demonstrated by our initial colloidal carbon experiment.
The broad vector distribution was reflected by bgalactosidase transgene expression in many tissues. After the 3 day time point, which showed extensive bgalactosidase activity in virtually all liver cells of the fetus, nonpreferentially localized clusters of cells started to appear at all later time points. Although pseudotransduction by b-galactosidase enzyme cannot be ruled out at 3 days postvector injection, the emergence of foci of b-galactosidase-positive cells was probably a result of ongoing fetal cell division leading to clonal expansion of cells with integrated vector as liver mass increases 23-fold from birth to 79 days. These focal clusters may represent clones of cells where vector integration into privileged genomic regions resulted in persistent expression whereas vector shutdown may have occurred for the majority of proviral integrations.
Both in the heart and skeletal muscle gene expression was undetectable before 7 and 14 days, respectively, but was consistently observed thenceforth. Although colloidal carbon marking was scarce in the fetal brain, we saw early and transient b-galactosidase expression in cerebral endothelia and then emerging expression in neuronal cells 79 days after injection. We also observed the late appearance of b-galactosidase-positive cells in the kidney tubules and lungs. These observations may reflect patterns of developmentally regulated expression of the CMV virus promoter. The existence of vector in fetal tissues at the molecular level was determined by PCR and sensitive Taqman PCR was used to determine vector spread to the germ-line by analysis of sperm. Virtually all tissues showed the presence of EIAV vector even after 1 year. Even though vector was found in the testes in this animal, the signal appeared weak suggesting low-level gene transfer had occurred, although this level was not quantified. Importantly, quantification by Taqman PCR showed no vector in sperm analysed 75 days postinjection in the mouse positive for gene transfer to the liver. The disparity between gene transfer found by direct PCR in tissue samples given in Table 1 and after histological analysis may be because of tissue specific gene expression or as a result of promoter shutdown which was more evident after X-gal staining of liver samples of treated animals killed from 3 days to 1 year. Lentiviruses are said to mediate higher transgene expression and to be more resistant to shutdown than classical MLV-based vectors. 31, 32 We chose the EIAV lentivirus as a novel and perhaps more acceptable alternative to HIV-1-based vectors for future human gene therapy applications given concerns over vector tolerance. Pseudotyping of this vector with the VSV-G envelope provides, as with other integrating vectors, a broad tissue tropism.
In utero application of an HIV-1 lentivirus vector by intraperitoneal and direct hepatic injection in early gestation rhesus monkeys resulted in low-level and transient gene expression predominantly in haematopoietic cells. 33 This contrasts with the prolonged transgene expression observed in preimmune fetal sheep 11, 13 and with the experiments reported here. Tran et al 13 also observed that a three-fold increase in titre of an MLV vector only yielded a two to eight-fold increase in stable transduction, implying the operation of additional factors. We suggest that the main determinant of expression longevity from integrating vectors is position-dependent expression shutdown. It has been postulated that as lentiviruses transduce nondividing cells, they may integrate their DNA into active sites of chromatin thus minimizing promoter silencing. 34 In the developing fetus such sites for vector integration may be more abundant than in the adult, and therefore virus delivery earlier in gestation may result in greater numbers of successful insertions in regions of the genome less prone to shutdown. As the CMV promoter is particularly prone to expression shutdown, 24 its replacement with tissue-specific mammalian promoters may further increase persistence of transgene expression and tissue specificity. Another important factor influencing the persistence of gene expression is the development of immune reactions against vector and the transgenic protein. Tran et al 13 have recently shown the development of postnatal tolerance to b-galactosidase after expression of this transgenic protein in preimmune fetal sheep. We have demonstrated a similar effect in mice after prenatal yolk sac vessel application of an The lack of gene expression after delivery into adult mice was not unexpected. An important influence on vector transduction is the possible inactivation of VSV-G pseudotyped virus by active complement present in adult mice. VSV-G inactivation by complement in human serum has also been described. 35 Therefore, higher doses of vector than those used in this study may be required to overcome a threshold dose needed for detectable transduction. Previously, an HIV-1-derived vector at higher infectious vector titres (2 Â 10 8 TU) showed lowlevel transduction (2.2%) of the liver of C57BL/6-SCID mice. 36 These levels were increased to 60% of hepatocytes by partial hepatectomy and a similar vector dose resulted in 10% hepatocyte expression of GFP in immunocompetent C57/Bl6 mice after portal vein infusion. 21 Vector dose is an important consideration for in utero gene delivery since potential hepatotoxicity could compromise fetal survival. Importantly, the dose of EIAV vector applied to fetal mice, which was similar to that delivered to the adult mice used in our study, resulted in high-level transduction of the fetus with over 90% fetal survival rate. Although not examined here adult gene expression may, however, occur over a longer time than the 3-day period examined here. The reason for such high hepatocyte gene transfer in the fetus is not entirely clear. Examination of virus stocks for the presence of replication-competent lentivirus was negative using assays for PERT activity and for the number of copies of the EIAV packaging signal, which did not increase over time in transduced cells grown in culture.
The fetal liver would probably have been exposed to about 50% of the vector at first passage from yolk sac vessel injection unlike the adult circulation that delivers the whole vector dose to the liver following portal vein administration. A contributory reason for the high-level transduction could be a lack of active complement in the MF-1 fetal mouse and therefore the threshold of vector required for fetal tissue transduction may be lower in the fetus. In addition, there may more available favourable chromosomal sites for virus integration 25 during fetal development, although we are not aware of data to support this hypothesis.
The diversity of tissues transduced by the VSV-Gpseudotyped EIAV-based vector and the longevity of gene expression achieved after prenatal gene delivery has important implications if reproducible in other species, particularly humans. Numerous inborn errors of metabolism may be treated by transduction of liver cells that could act as natural (eg clotting factors) or ectopic (eg erythropoietin) factories of systemically required proteins. Inherited genetic diseases of the skeletal and cardiac muscle and those affecting the CNS could benefit from the observed muscular and neuronal tropism of VSV-G-pseudotyped EIAV-based vectors. Nevertheless, the precise nature of the transgene product may necessitate the restriction of its expression to certain tissues or cells; this may involve control from a tissue-specific promoter or the use of a different envelope pseudotype.
The persistent, highly efficient and apparently nonpathogenic gene transfer achieved following in utero injection of the EIAV-based vector shown in this study suggests that fetal gene therapy with this vector may offer an effective novel approach to the treatment and prevention of many life-threatening genetic diseases manifesting prenatally and after birth.
Methods
Production of high titre EIAV and analysis for replication competent virus Human embryonic kidney 293T cells were used to produce SMART2Z EIAV particles. 22, 37 SMART2Z is an EIAV vector expressing the b-galactosidase gene driven by the CMV promoter. It also contains the central polypurine tract from EIAV (cppt) 38 and the WPRE element from the woodchuck hepatitis virus. 39 Cells were grown in DMEM supplemented with 10% fetal calf serum and transfected with plasmid vectors to transiently produce infectious virus particles as previously described.
1 Virus titration was determined using TaqMan assay as previously described 40 to be 10 9 TU/ml. To assay for the presence of replication competent virus, stock EIAV preparations were placed onto D17 canine cells by seeding cells onto 12-well culture dishes at 8 Â 10 4 cells/well followed by the addition of serially diluted virus. These cells were used for this purpose as they have previously been shown to support EIAV replication. 41, 42 Virus was left on cells for 24 h before removal. Cells were washed twice in PBS, then re-fed with fresh medium and incubated for a further 24 h. Supernatant from these cells was placed onto fresh D17 cells and left overnight followed by 24 h expression. The absence of b-galactosidase staining confirmed the absence of replication-competent vector.
Assays to detect the presence of replicationcompetent lentiviruses in the viral preparations
To detect the presence of replication-competent EIAV virus, 293T cells were seeded into 12-well plates at 1 Â 10 5 cells per well. These cells were transduced 24 h later in duplicate with three viral vector preparations. The cells were passaged one in five every 3-4 days. Supernatant and cellular DNA were isolated at various time points. The supernatant samples were assayed for PERT activity and the cellular DNA was analysed for integrated copies of EIAV genome. 43 The method (product-enhanced reverse transcriptase) used to determine the amount of RT present in the samples has been described by MartinRendon et al. 27 No replication-competent EIAV virus was detected for virus preparations.
PCR for vector spread to mouse tissue and for germline transmission For tissue samples, harvested tissues were macerated in PBS, then pelleted by centrifugation and resuspended in buffer containing 200 ml of 0.5 M EDTA, 100 ml of 0.1 M Tris-HCl, 250 ml of 10% SDS and 100 ml of 0.1 M NaCl. A volume of 3 ml of proteinase K was added (stock 10 mg/ ml) and 25 ml of 0.039 M DTT and incubated at 371C overnight. A standard phenol/chloroform extraction was used followed by ethanol precipitation. DNA was resuspended in sterile distilled water. PCR of fetally treated sample genomic DNAs were subjected to PCR To analyse sperm samples for vector presence, one male injected in utero with SMART2Z and which showed long-term b-galactosidase expression histologically in biopsied liver was mated 75 days after vector delivery with untreated females overnight. Two inseminated females were killed and the semen washed from the uteri was confirmed as containing sperm by microscopy. Half of the semen sample was added to 250 ml DNA buffer and subjected to purification procedures (described above). Sample DNA quantification was made using PCR primers to murine GADPH using primers (F) 5 0 -CGGATTTGGCCGTATTGG-3 0 and (R) 5 0 -TGGCAA CAATCTCCACTTTGC-3 0 and TaqMan probe primer 5 0 FAM,3 0 Tamra, 5 0 CCTGGTCACCAGGGCTGCCATT-3 0 . Control sperm and liver sample DNAs from an untreated MF-1 mouse were used as a standard for GAPDH and as a negative control for the TaqMan assay used to investigate the presence of the EIAV packaging signal in the sperm sample from the treated mouse. Taqman assay for the presence of vector packaging signal sequence in treated samples has been previously described. 27 EIAV-transduced liver was used as a positive control for vector.
Animal procedures
Isofluorane anaesthesia was used for all procedures. The uteri were exposed through a full-depth midline laparotomy in three female MF1 mice (B&K Ltd, UK) at 16 days gestation. Trans-uterine injections of 20 ml of EIAV viral vector at 1 Â 10 9 TU/ml into a peripheral yolk sac vessel were given using a 34-gauge needle (Hamilton UK). Per dam, up to five fetuses were injected and then marked subcutaneously with colloidal carbon. Dams recovered in a warm cage after wound closure. Some fetuses were injected via the yolk sac vessel with 20ml colloidal carbon and harvested 5 min later. 26 Two adult mice received 50 ml 1 Â 10 9 TU/ml vector via the hepatic portal vein. In four mice, a 3 mm 3 liver biopsy was excised through a small full-depth laparotomy. All procedures were approved by the Imperial College Ethical Review Committee and the Home Office.
Tissue harvest
Animals were euthanized with isofluorane anaesthetic. The liver and other organs were placed in 100% ethanol for 2 h before staining for b-galactosidase transgene expression using X-gal solution. 2 Tissue was fixed in 10% formaldehyde solution, paraffin embedded, sectioned, and counterstained with neutral red.
FACS analysis
Livers excised from 15 day gestation fetuses were passed through a 70-100 mm cell strainer and resuspended at 2.3 Â 10 6 cells/ml in PBS+3% FBS. Aliquots were incubated with antibodies against either albumin (late hepatocyte marker), alpha-fetoprotein (early hepatocyte marker), or with a combination of antibodies against CD45.2, TER119 and c-Kit (haematopoietic cell marker), at a concentration of 1 mg antibody per million cells. After secondary conjugation with the appropriate FITClabelled antibodies (DAKO, UK and Molecular Probes, USA) analysis was performed on 10 000 events using a FACSCalibur counter (Becton Dickinson, USA). Gating was based on the negative control staining profiles. 44 
